Abstracts tagged "clinical remission"

Abstract Number: 0140 • ACR Convergence 2021
Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis
Jana Ziob¹, Charlotte Behning¹, Peter Brossart², Thomas Bieber¹, Dagmar Wilsmann-Theis³ and Valentin Schäfer⁴, ¹University Hospital Bonn, Bonn, Germany, ²Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany, ³Department for Dermatology and Allery, University Hospital Bonn, Bonn, Germany, ⁴Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany
Background/Purpose: An interdisciplinary approach involving dermatologists and rheumatologists is required for the management of patients with psoriatic arthritis (PsA). The purpose of our study was…
Abstract Number: 0931 • ACR Convergence 2021
Early Improvement in Disease Activity Indices Predicts Achievement of Long-term Clinical Remissions, ASDAS Inactive Disease and Low BASDAI with Normal CRP, During TNF-α-inhibitor Therapy in Patients with Ankylosing Spondylitis
Sang Jin Lee, Na Ri Kim and Eon Nam, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea
Background/Purpose: As biologic agents including tumor necrosis factor (TNF)-α inhibitors (TNFi) have been proven to improve enormously clinical outcomes for patients with ankylosing spondylitis (AS),…
Abstract Number: 1300 • ACR Convergence 2021
Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Hamilton, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada
Background/Purpose: We have previously shown that prolonged clinical remission for ≥10 years is associated with significantly less damage accrual in inception patients with systemic lupus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].